Navidea raises $25M to market Lymphoseek

Navidea Biopharmaceuticals ($NAVB) has closed a $25 million debt financing with GE Capital, planning to use the funds to amp up commercialization for Lymphoseek, the company's FDA-approved cancer diagnostic tool. In addition, Navidea will put some of the cash toward its pipeline, which includes diagnostic imaging agents for Alzheimer's and Parkinson's. More